Goldman Sachs Maintains Price Target on Amgen (AMGN) Before Key Trial Readouts

Amgen Inc. (NASDAQ:AMGN) ranks among the Best Low Volatility Investments in December 2025. Goldman Sachs reaffirmed its $400 price target and Buy rating for Amgen Inc. (NASDAQ:AMGN) on November 25 ahead of two Phase 2 updates for the company’s obesity medication MariTide, which are anticipated by year’s end. Following previously disclosed induction results from Part 1, the firm anticipates that Amgen will provide maintenance data in obesity from Part 2 of its Phase 2 trial.

Pixabay/Public Domain

Goldman Sachs looked for long-term weight loss with reduced or occasional dosage and little gastrointestinal side effects in the obesity maintenance data. According to the firm, patients were only qualified for the maintenance phase if they experienced a weight loss of more than 15% in Part 1.

In the Phase 2 study, MariTide showed up to a 20% average weight loss in patients with obesity without Type 2 diabetes (T2D) and a roughly 17% average weight loss in those with T2D. MariTide weight loss was also associated with improvements in pre-specified cardiometabolic parameters, such as waist circumference and blood pressure.

Amgen Inc. (NASDAQ:AMGN) discovers, develops, manufactures, and delivers human therapeutics worldwide. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies.

While we acknowledge the potential of AMGN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than AMGN and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.